Macrolide Pharmaceuticals Appoints Sumit Aggarwal President and CEO
Company Chief Financial Officer and Chief Business Officer Assumes Top Leadership Post
WATERTOWN, MA – MARCH 14, 2019 – Macrolide Pharmaceuticals, an early stage research-based pharmaceutical company, announced today it has appointed Sumit Aggarwal as President and Chief Executive Officer. Aggarwal, who has served as the company’s Chief Financial Officer and Chief Business Officer since August 2018, succeeds Mahesh Karande who is leaving the company.
“Sumit has a strong track record of raising capital to support investment in promising companies and has a keen understanding of Macrolide Pharmaceuticals, our scientific platform, and our potential to build value as a promising, early-stage research company,” said Joe Zakrzewski, Chairman of Macrolide’s Board of Directors.
Sumit has more than 20 years in pharmaceutical and biotechnology commercial operations, investment management, and management consulting with a focus on successfully transforming companies through innovation and growth.
Prior to joining Zikani, he reinvigorated growth and profitability at Progenity, raised $125 million in capital, and built a novel drug delivery-based GI pipeline. He also held leadership roles in healthcare and biotechnology at Adage Capital and as an Associate Partner at McKinsey & Company in its healthcare practice.
Sumit has an MBA with distinction from the Johnson School, Cornell University, and a Bachelor of Technology with Honors in Chemical Engineering from the Indian Institute of Technology, Kharagpur.
About Macrolide Pharmaceuticals
Macrolide Pharmaceuticals, based in Watertown, MA, is developing novel antibiotics for the treatment of serious, multi-drug resistant Gram-negative infections. The company’s core discovery and development program leverages a groundbreaking synthetic chemistry platform developed by Dr. Andrew Myers at Harvard University. Macrolide Pharmaceuticals’ lead program is in late preclinical development, and the company’s chemistry platform has the potential to be used to develop therapeutics to treat multiple infections conditions.
Contacts: Outcomes Communication Group